Tuesday, November 5, 2024
HomeTagsATG-101

ATG-101

Antengene Announces First Patient Dosed in the PROBE-CN Study of ATG-101

Antengene Corporation Limited, a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology,...

Antengene Announces IND Approval in China for the Phase I Study of ATG-101 for the Treatment of Solid Tumors and Non-Hodgkin Lymphoma

Antengene Corporation Limited, a leading innovative commercial stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and...

First Patient Dosed in Australia in ATG-101 First-in-Human Trial

Antengene Corporation Limited, a leading innovative global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in hematology and oncology, announced...
0FansLike
3,912FollowersFollow
0SubscribersSubscribe
spot_img

Hot Topics